Pentraxins, anti-pentraxin antibodies, and atherosclerosis

Clinical Reviews in Allergy and Immunology

Volumn 37, Issue 1, 2009, Pages 36-43

  Bassi, N ^a   Zampieri, S ^a   Ghirardello, A ^a   Tonon, M ^a   Zen, M ^a   Cozzi, F ^a   Doria, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti pentraxins autoantibodies; Atherosclerosis; Autoantibodies; Autoimmunity; Complement system; Pentraxins

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; C REACTIVE PROTEIN; PENTRAXIN 3; SERUM AMYLOID P;

ATHEROSCLEROSIS; AUTOIMMUNITY; BLOOD; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; REVIEW;

ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; C-REACTIVE PROTEIN; HUMANS; IMMUNITY, INNATE; SERUM AMYLOID P-COMPONENT;

EID: 68749106055     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-008-8098-6     Document Type: Review

References (97)

1. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126
2. Hansson GK (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Cir Res 91:281-291
3. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508-518
4. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
5. Shoenfeld Y, Sherer Y, Harats D (2001) Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 22:293-295 (Pubitemid 32675235)
6. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62:1071-1077 (Pubitemid 37323571)
7. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337-3347 (Pubitemid 43739380)
8. Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. Artherioscler Thromb Vasc Biol 25:1776-1785
9. Doria A, Sherer Y, Meroni PL, Shoenfeld Y (2005) Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 31:355-362 (Pubitemid 40732493)
10. Nilsson J, Hansson GK (2008) Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 263:464-478 (Pubitemid 351533555)
11. Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F et al (2007) OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 7:52-58 (Pubitemid 47633392)
12. Szyper Kravitz M, Pitashny M, Shoenfeld Y (2005) Protective molecules - C-reactive protein (CRP), serum amyloid P (SAP), Pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (ApoA1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 25:582-591 (Pubitemid 43011749)
13. Szyper Kravitz M, Shoenfeld Y (2006) Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2:481-490
14. Kobayashi K, Tada K, Itabe H, Ueno T, Liu PH, Tsutsumi A et al (2007) Distinguished effect of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 16:929-938
15. Shishehbor MH, Bhatt DL (2004) Inflammation and atherosclerosis. Curr Atheroscler Rep 6:131-139 (Pubitemid 38914958)
16. Gordon PA, George J, Khamatshta M, Harats D, Hughes G, Shoenfeld Y (2001) Atherosclerosis and autoimmunity. Lupus 10:249-252 (Pubitemid 32332145)
17. Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR (1999) Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 36:261-268 (Pubitemid 29281854)
18. Ando B, Wiedmer T, Hamilton KK, Sims PJ (1988) Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J Biol Chem 263:11907-11914
19. Thorbjornsdottir P, Kolka R, Gunnarsson E, Bambir SH, Thorgeirsson G, Kotwal GJ et al (2005) Vaccinia virus complement control protein diminishes formation of atherosclerotic lesions: complement is centrally involved in atherosclerotic disease. Ann NY Acad Sci 1056:1-15 (Pubitemid 43030963)
20. Pauletto P, Puato M, Faggin E, Santipolo N, Pagliara V, Zoleo M et al (2000) Specific cellular features of atheroma associated with development of neointima after carotid endrterectomy: the carotid atherosclerosis and restenosis study. Circulation 102:771-778 (Pubitemid 30643285)
21. Taleb S, Tedgui A, Mallat Z (2008) Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 263:489-499 (Pubitemid 351533554)
22. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanism regulating Th1 immune responses. Annu Rev Immunol 21:713-758 (Pubitemid 37174546)
23. Cheng X, Yu X, Ding YI, Fu Q, Xie J, Tang T et al (2008) The Th17/Treg imbalance in patients with acute coronary sindrome. Clin Immunol 127:89-97
24. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ et al (1999) Perturbation of the T-cells repertoire in patients with unstable angina. Circulation 100:2135-2139
25. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ (2003) CD28 loss in senescent CD4+T cells: reversal by interleukin-12 stimulation. Blood 101:3543-3549 (Pubitemid 36857940)
26. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vando G et al (2004) CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744-2748 (Pubitemid 38737922)
27. Lehtimäki T, Lehtinen S, Solakivi T, Nikkilä M, Joakkola O, Jokela H et al (1999) Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Artherioscler Thromb Vasc Biol 19:23-27 (Pubitemid 29031908)
28. George J, Harats D, Bakshi E, Adler Y, Levy Y, Gilburd B et al (1999) Anti-oxidized low density lipoprotein antibodiy determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 68:263-266 (Pubitemid 29301886)
29. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I et al (1998) Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138:147-152 (Pubitemid 28255163)
30. Ameli S, Hulgtgardh-Nilsso A, Regnström J, Calara F, Yano J, Crcek B et al (1996) Effect of immunization with homologous LDL and oxidized on early atherosclerosis in hypercholesterolemic rabbits. Artherioscler Thromb Vasc Biol 16:1074-1079 (Pubitemid 26266910)
31. Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y (2005) Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 14:736-741 (Pubitemid 41413302)
32. Koike T, Ichikawa K, Kasahara H, Atsumi T, Tsutsumi A, Matsuura E (1998) Epitopes on beta2-GPI recognized by anticardiolipin antibodies. Lupus 7:S14-S17 (Pubitemid 28484573)
33. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneidermen J et al (1999) Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implication for lesion progression. Circulation 99:2227-2230 (Pubitemid 29201126)
34. George J, Shoenfeld Y, Harats D (1999) The involvement of beta2-glycoprotein I (beta2-GPI) in human and murin atherosclerosis. J Autoimmun 13:57-60 (Pubitemid 29367007)
35. Sherer Y, Shemesh J, Tenenbaum A, Praprotnik S, Harats D, Fisman EZ, Blank M et al (2000) Coronary calcium and anticardiolipin antibody are elevated in patients with typical chest pain. Am J Cardiol 86:1306-1311
36. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fisman EZ et al (2001) Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 95:20-24 (Pubitemid 32506956)
37. Mandal K, Foteinos G, Jahangiri M Xu Q (2005) Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus 14:742-746 (Pubitemid 41413303)
38. Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23:337-366 (Pubitemid 40563173)
39. Mantovani A, Garlanda C, Doni A, Bottazzi B (2008) Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 28:1-13
40. Thompson D, Pepys MB, Wood SP (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7:169-177 (Pubitemid 29159702)
41. Du Clos TW, Mold C (2004) C-reactive protein. An activator of innate immunity and a modulator of adaptive immunity. Immunol Res 30:261-277 (Pubitemid 39546229)
42. Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A et al (2007) Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kB and C/EBPβ activation. J Biol Chem 282:27229-27238 (Pubitemid 47501976)
43. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111:1805-1812 (Pubitemid 38057722)
44. Szalai AJ (2002) The antimicrobial activity of C-reactive protein. Microbes Infect 4:201-205
45. Du Clos (1996) The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Med Biol Res 23:253-260
46. Gershov D, Kim SJ, Brot N, Elkon KB (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustain anti-inflammatory innate immune response: implication for systemic autoimmunity. J Exp Med 192:1353-1363
47. Khreiss T, Jozsef L, Potempa LA, Filep JG (2004) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109:2016-2022 (Pubitemid 38544493)
48. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342(12):836-843 (Pubitemid 30165206)
49. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K et al (2008) Chemokines and cardiovascular risk. Artherioscler Thromb Vasc Biol (in press)
50. Morrow DA, de Lemos JA, Sabatine MS, Wiviot SD, Blazing MA, Shui A et al (2006) Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocol Trial. Circulation 114:281-288 (Pubitemid 44297094)
51. Morrow DA, Rifai N, Antman EM, Weiner DN, McCabe CH, Cannon CP et al (1998) C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31:1460-1465 (Pubitemid 28273285)
52. Engström G, Hedblad B, Tydén P, Lindgärde F (2008) Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. Atherosclerosis (in press)
53. Rosenau BJ, Costenbader KH, Schur PH (2008) C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis. Vasc Med 13:25-28 (Pubitemid 351596925)
54. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A (2008) Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 20:1-7
55. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J et al (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesion of human coronary arteries. Artherioscler Thromb Vasc Biol 18:1386-1392 (Pubitemid 28421875)
56. Zhang YX, Cliff WJ, Schoefl GI, Higgins G (1999) Coronary Creactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 145:375-379 (Pubitemid 29359147)
57. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J (2007) Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci U S A 104:13768-13773 (Pubitemid 350003395)
58. -/- mice. Atherosclerosis 196:248-255
59. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I (2007) C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 43:780-791 (Pubitemid 350166380)
60. Ryu J, Lee CW, Shin JA, Park CS, Kim JJ, Park SJ et al (2007) Fcgamma RIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res 75:555-565 (Pubitemid 47080970)
61. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I (2008) Human C-reactive protein promotes oxidized low-density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 49:1015-1023
62. Devaraj S, Dasu MR, Singh U, Rao LVM, Jialal I (2008) Creactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (in press)
63. Taskinen S, Hyvönen M, Kovanen PT, Meri S, Pentikäinen MO (2005) C-reactive protein binds to 3β-OH group of cholesterol in LDL particles. Biochem Biophys Res Commun 329:1208-1216 (Pubitemid 40568699)
64. Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barssom H, Suriyaphol P et al (2004) Possible protective roel for C-reactive protein in atherogenesis. Complement activation by modified lipoproteins halts before detrimental sequence. Circulation 109:1870-1876 (Pubitemid 38509122)
65. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL et al (1994) Human serum amyloid P component is an invariant costituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A 91:5602-5606 (Pubitemid 24174376)
66. Hutchinson WL, Hohenester E, Pepys MB (2000) Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol Med 6:482-493
67. Lin BF, KU NO, Zahedi K, Whitehead AS, Mortensen RF (1990) IL-1 and IL-6 mediate increased production and synthesis by hepatocytes of acute-phase serum amyloid P-component (SAP). Inflammation 14:297-313
68. Hamazaki H (1995) Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer 's beta-amyloid peptide. J Biol Chem 270:10392-10394
69. Koenig W (2007) Serum amyloid P component and cardiovascular disease. Is there a sensible link? Artherioscler Thromb Vasc Biol 27:698-700
70. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM (2007) Serum amyloid P and cardiovascular disease in older men and women. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 27:352-358 (Pubitemid 46143051)
71. Noursadeghi M, Bickerstaff MC, Galimore JR, Herbert J, Cohen J, Pepys MB (2000) Role of serum amyloid P component in bacteria infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A 97:14584-14589 (Pubitemid 32016619)
72. Rocken C, Tautenhahn J, Buhling F, Sachwitz D, Vockler S, Goette A et al (2006) Prevalence and pathology of amyloid in atherosclerotic arteries. Artherioscler Thromb Vasdc Biol 26:676-677
73. Myers SL, Jones S, Janh TR, Morten IJ, Tennent GA, Hewitt EW et al (2006) A systemic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neutral pH. Biochemistry 45:2311-2321 (Pubitemid 43271331)
74. Mac Rail CA, Stewart CR, Mok YF, Gunzburg MJ, Perugini MA, Lawrence LJ et al (2004) Non-fibrillar components of amyloid deposits mediates the self-association and tangling of amyloid fibrils. J Biol Chem 279:21038-21045 (Pubitemid 38656505)
75. Pilling D, Tucker NM, Gomer RH (2006) Aggregated IgG inhibits the differentiation of of human fibrocytes. J Leucok Biol 79(6):1242-1251 (Pubitemid 44835558)
76. Stewart CR, Tseng AA, Mok YF, Staples MK, Schiesser CH, Lawrence LJ et al (2005) Oxidation of low-density lipoproteins induces amyloid like structures that are recognized by macrophages. Biochemistry 44:9108-9116 (Pubitemid 40943225)
77. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A et al (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267(31):22190-22197
78. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G et al (1997) Multimer formation and ligand recognition by the long pentraxin PTX3. J Biol Chem 272:32817-32823
79. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B et al (2001) Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 29:1404-1407 (Pubitemid 32641804)
80. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM (2008) The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum (in press)
81. Mantovani A, Garlanda C, Bottazzi B (2003) Pentraxin3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 21:S43-S47 (Pubitemid 36588649)
82. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ et al (2003) Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 33:465-473 (Pubitemid 36267612)
83. van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini P, Mantovani A et al (2004) The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 50:2667-2674 (Pubitemid 39062730)
84. Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA et al (2006) The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 80(1):87-95 (Pubitemid 44835529)
85. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G et al (2002) Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Artherioscler Thromb Vasc Biol 22:782-787 (Pubitemid 34517789)
86. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G et al (2004) The long pentraxin PTX3 upregulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 76:203-209 (Pubitemid 38857188)
87. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F et al (2000) PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102:636-641 (Pubitemid 30640663)
88. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P et al (2004) Lipis Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349-2354 (Pubitemid 39407338)
89. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T et al (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 155:75-81 (Pubitemid 350234768)
90. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22:10-14
91. Savchenko AS, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G et al (2008) Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 215:48-55 (Pubitemid 351619875)
92. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G et al (2004) Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175:221-228 (Pubitemid 38942901)
93. Sjowall C, Eriksson P, Almer S, Skogh T (2002) Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 19:155-160 (Pubitemid 35341865)
94. Sjowall C, Bengtsson AA, Sturfel G, Skogh T (2004) Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 6:R87-R94
95. Zandman-Goddard G, Blank M, Langevitz P, Slutsky L, Pras M, Levy Y et al (2005) Anti-serum amyloid P (SAP) antibodies in SLE patients correlate with the disease activity. Ann Rheum Dis 64:1698-1702 (Pubitemid 41667142)
96. Figueredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E et al (2006) Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 33:1980-1986
97. Bassi N, Ghirardello A, Zampieri S, Rampudda M, Atzeni F, Sarzi-Puttini P et al (2008) Anti-PTX3: are they real? Clin Exp Rheumatol 26(Suppl 48):S-89